Clinical Trial Update: Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing a suprachoroidal sustained-release formulation (OXU-001) to the dexamethasone intravitreal implant (Ozurdex) for diabetic macular edem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• OXU-001 (suprachoroidal sustained-release ocular implant)
• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: Oxular Limited | Conditions: Diabetic Macular Edema | Phase 2 | Status: COMPLETED | Results posted: 2025-09-03